EPR: Evidence and fallacy

Journal of Controlled Release

Volumn 190, Issue , 2014, Pages 451-464

  Nichols, Joseph W ^a   Bae, You Han ^b  

^a University of Utah   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Clinical efficacy; Drug delivery; Enhanced permeability and retention; Intratumoral distribution; Tumor models

Indexed keywords

CONTROLLED DRUG DELIVERY; DRUG DELIVERY; TUMORS;

CANCER DRUG DELIVERIES; CLINICAL EFFICACY; ENHANCED PERMEABILITY AND RETENTIONS; FUNDAMENTAL PRINCIPLES; INTERSTITIAL FLUID PRESSURES; INTRATUMORAL DISTRIBUTION; NANO-SIZED DRUG CARRIERS; TUMOR MODELS;

TARGETED DRUG DELIVERY; TUMORS;

DAUNORUBICIN; DOXORUBICIN; NANOCARRIER; PACLITAXEL; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER; ANTINEOPLASTIC AGENT; DRUG CARRIER; MALEIC ANHYDRIDE; NANOPARTICLE; POLY(MALEIC ACID-STYRENE)NEOCARZINOSTATIN; POLYSTYRENE DERIVATIVE; ZINOSTATIN; BLEOMYCIN; COLLAGEN; IODINATED POPPYSEED OIL; LIPOSOME; MACROGOL; VINCRISTINE;

ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER SUSCEPTIBILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ENHANCED PERMEABILITY AND RETENTION; HUMAN; LONGEVITY; MALIGNANT NEOPLASTIC DISEASE; MOLECULARLY TARGETED THERAPY; NONHUMAN; PARTICLE SIZE; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL PHENOMENA; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TISSUE PRESSURE; TUMOR BLOOD FLOW; TUMOR MODEL; TUMOR VASCULARIZATION; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; HISTORY; NEOPLASMS; PATHOLOGY; PERMEABILITY; ANTINEOPLASTIC ACTIVITY; CIRCULATION TIME; DRUG DISTRIBUTION; ENDOTHELIUM CELL; MOLECULAR WEIGHT; MONONUCLEAR PHAGOCYTE; PHARMACOLOGICAL PARAMETERS; REVIEW; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; HISTORY, 20TH CENTURY; HUMANS; MALEIC ANHYDRIDES; NANOPARTICLES; NEOPLASMS; PERMEABILITY; POLYSTYRENES; ZINOSTATIN;

EID: 84906783643     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.03.057     Document Type: Review

References (211)

1. K. Strebhardt, and A. Ullrich Paul Ehrlich's magic bullet concept: 100 years of progress Nat. Rev. Cancer 8 6 2008 473 480 (Pubitemid 351752547)
2. P. Ehrlich Aus theorie und praxis der chemotherapie 1911
3. H.E. Varmus Banquet Speech Nobel Banquet 1989
4. L.S. Goodman Nitrogen mustard therapy J. Am. Med. Assoc. 132 no. 3 Sep. 1946 126
5. S. Farber, and L.K. Diamond Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid N. Engl. J. Med. 238 23 1948 787 793
6. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 1 2000 57 70 (Pubitemid 30046295)
7. N. Howlader, A. Noone, M. Krapcho, N. Neyman, R. Aminou, S. Altekruse, C. Kosary, J. Ruhl, Z. Tatalovich, H. Cho, A. Mariotto, M. Eisner, D. Lewis, H. Chen, E. Feuer, and K. Cronin SEER Cancer Statistics Review, 1975-2009 2010 (Bethesda, MD)
8. T.E. Arpawong, S.H. Richeimer, F. Weinstein, A. Elghamrawy, and J.E. Milam Posttraumatic growth, quality of life, and treatment symptoms among cancer chemotherapy outpatients Health Psychol. 32 4 Apr. 2013 397 408
9. P. Schofield, K. Gough, and A. Ugalde Cancer Treatment Survey (CaTS): development and validation of a new instrument to measure patients' preparation for chemotherapy and radiotherapy Psycho-Oncology 21 2012 307 315
10. E.K. Rowinsky, E.A. Eisenhauer, V. Chaudhry, S.G. Arbuck, and R.C. Donehower Clinical toxicities encountered with paclitaxel (Taxol) Semin. Oncol. 20 no. 4 Suppl. 3 Aug. 1993 1 15 (Pubitemid 23239390)
11. J.T. Hartmann, and H.-P. Lipp Toxicity of platinum compounds Expert. Opin. Pharmacother. 4 6 Jun. 2003 889 901 (Pubitemid 36722480)
12. R.B. Weiss The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol. 19 6 Dec. 1992 670 686 (Pubitemid 23004844)
13. M.R. Boyd, and K.D. Paull Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen Drug Dev. Res. 34 2 Feb. 1995 91 109
14. D. Schrama, R.A. Reisfeld, and J.C. Becker Antibody targeted drugs as cancer therapeutics Nat. Rev. Drug Discov. 5 2 Mar. 2006 147 159
15. A.A. Gabizon, D. Goren, A.T. Horowitz, D. Tzemach, A. Lossos, and T. Siegal Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals Adv. Drug Deliv. Rev. 24 2 1997 337 344 (Pubitemid 27112652)
16. A.A. Gabizon Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes Cancer Res. 52 4 Feb. 1992 891 896
17. R.K. Jain, and T. Stylianopoulos Delivering nanomedicine to solid tumors Nat. Rev. Clin. Oncol. 7 11 Nov. 2010 653 664
18. H. Ringsdorf Structure and properties of pharmacologically active polymers J. Polym. Sci. Polym. Symp. 51 1 1975 135 153
19. A.T. Florence 'Targeting' nanoparticles: the constraints of physical laws and physical barriers J. Control. Release 164 2 Dec. 2012 115 124
20. J.W. Nichols, and Y.H. Bae Odyssey of a cancer nanoparticle: from injection site to site of action Nano Today 7 6 Dec. 2012 606 618
21. A.S. Mikhail, and C. Allen Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissue and cellular levels J. Control. Release 138 3 Sep. 2009 214 223
22. M. Juweid, R. Neumann, C. Paik, M.J. Perez-bacete, J. Sato, W. Van Osdol, and J.N. Weinstein Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier Cancer Res. 52 1992 5144 5153
23. H. Lee, H. Fonge, B. Hoang, R.M. Reilly, and C. Allen The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles Mol. Pharm. 7 4 Aug. 2010 1195 1208
24. E.A. Azzopardi, E.L. Ferguson, and D.W. Thomas The enhanced permeability retention effect: a new paradigm for drug targeting in infection J. Antimicrob. Chemother. 68 2 Feb. 2013 257 274
25. J. Fang, H. Nakamura, H. Maeda, and Y. Matsukado The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv. Drug Deliv. Rev. 63 3 Mar. 2011 136 151
26. T. Konno, H. Maeda, K. Iwai, S. Maki, S. Tashiro, M. Uchida, and Y. Miyauchi Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium Cancer 54 11 Dec. 1984 2367 2374 (Pubitemid 15223375)
27. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS Cancer Res. 46 12 Pt 1 1986 6387 6392 (Pubitemid 17221789)
28. M.R. Dreher, W. Liu, C.R. Michelich, M.W. Dewhirst, F. Yuan, and A. Chilkoti Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers J. Natl. Cancer Inst. 98 5 Mar. 2006 335 344 (Pubitemid 43338213)
29. A.J. Leu, D.A. Berk, A. Lymboussaki, K. Alitalo, and R.K. Jain Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation Cancer Res. 60 16 Aug. 2000 4324 4327 (Pubitemid 32103603)
30. T. Roose, P.A. Netti, L.L. Munn, Y. Boucher, and R.K. Jain Solid stress generated by spheroid growth estimated using a linear poroelasticity model Microvasc. Res. 66 3 Nov. 2003 204 212 (Pubitemid 37373595)
31. D.M. McDonald, and P. Baluk Significance of blood vessel leakiness in cancer Cancer Res. 62 18 Sep. 2002 5381 5385 (Pubitemid 35024617)
32. H. Maeda Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects Bioconjug. Chem. 21 5 May 2010 797 802
33. M.E. Gindy, and R.K. Prud'homme Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy Expert Opin. Drug Deliv. 6 no. 8 Aug. 2009 865 878
34. K. Kim, J.H. Kim, H. Park, Y.-S. Kim, K. Park, H. Nam, S. Lee, J.H. Park, R.-W. Park, I.-S. Kim, K. Choi, S.Y. Kim, K. Park, and I.C. Kwon Tumor-homing multifunctional nanoparticles for cancer theragnosis: simultaneous diagnosis, drug delivery, and therapeutic monitoring J. Control. Release 146 2 Sep. 2010 219 227
35. K. Greish Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines J. Drug Target. 15 7-8 Jan. 2008 457 464 (Pubitemid 47209047)
36. T. Flynn, and C. Wei The pathway to commercialization for nanomedicine Nanomedicine 1 1 Mar. 2005 47 51 (Pubitemid 43963613)
37. D.L. Stirland, J.W. Nichols, S. Miura, and Y.H. Bae Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice J. Control. Release 172 3 Oct. 2013 1045 1064
38. T. Hirano, H. Ringsdorf, and D.S. Zaharko Antitumor activity of monomeric and polymeric cyclophosphamide derivatives compared with in vitro hydrolysis Cancer Res. 40 7 Jul. 1980 2263 2267 (Pubitemid 10082236)
39. M. Szekerke, and J.S. Driscoll The use of macromolecules as carriers of antitumor drugs Eur. J. Cancer 13 6 1977 529 537 (Pubitemid 8126101)
40. H. Sezaki, and M. Hashida Macromolecule-drug conjugates in targeted cancer chemotherapy Crit. Rev. Ther. Drug Carrier Syst. 1 1 Jan. 1984 1 38 (Pubitemid 15062288)
41. F. Moolten Antitumor effects of antibody-diphtheria toxin conjugates: use of hapten-coated tumor cells as an antigenic target J. Natl. Cancer Inst. 49 4 Oct. 1972 1057 1062
42. T. Bumol, and Q. Wang Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth Proc. Natl. Acad. Sci. 80 2 Jan. 1983 529 533 (Pubitemid 13174642)
43. E.A. Swabb, J. Wei, and P.M. Gullino Diffusion and convection in normal and neoplastic tissues Cancer Res. 34 10 Oct. 1974 2814 2822
44. R.K. Jain Transport of molecules in the tumor interstitium: a review Cancer Res. 47 12 Jun. 1987 3039 3051 (Pubitemid 17082621)
45. L.J. Nugent, and R.K. Jain Extravascular diffusion in normal and neoplastic tissues Cancer Res. 44 1 Jan. 1984 238 244 (Pubitemid 14177745)
46. G.W. Pasternak, S.C. March, I. Parikh, S.H. Snyder, and P. Cuatrecasas Macromolecular naloxone: a novel long-acting polymer-bound drug Life Sci. 18 9 1976 977 981
47. S.W. O'Connor, and W.F. Bale Accessibility of circulating immunoglobulin G to the extravascular compartment of solid rat tumors Cancer Res. 44 9 Sep. 1984 3719 3723 (Pubitemid 14041580)
48. L.E. Gerlowski, and R.K. Jain Microvascular permeability of normal and neoplastic tissues Microvasc. Res. 31 3 1986 288 305 (Pubitemid 16076428)
49. B. Sylven, and I. Bois Protein content and enzymatic assays of interstitial fluid from some normal tissues and transplanted mouse tumors Cancer Res. 20 6 Jul. 1960 831 836
50. H.F. Dvorak, J.A. Nagy, J.T. Dvorak, and A.M. Dvorak Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules Am. J. Pathol. 133 1 Oct. 1988 95 109
51. J.L. Mego, and J.D. McQueen The uptake of labeled proteins by particulate fractions of tumor and normal tissues after injection into mice Cancer Res. 25 no. 6-Part-1 Jul. 1965 865 869
52. L.E. Gerlowski, and R.K. Jain Effect of hyperthermia on microvascular permeability to macromolecules in normal and tumor tissues Int. J. Microcirc. Clin. Exp. 4 4 Jan. 1985 363 372
53. E.J. Potchen, J. Kinzie, C. Curtis, B.A. Siegel, and R.K. Studer Effect of irradiation on tumor microvascular permeability to macromolecules Cancer 30 3 Sep. 1972 639 642
54. T. Tsuruo, H. Iida, S. Tsukagoshi, and Y. Sakurai Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors Cancer Res. 42 11 Nov. 1982 4730 4733 (Pubitemid 13205981)
55. B. Endrich, H.S. Reinhold, J.F. Gross, and M. Intaglietta Tissue perfusion inhomogeneity during early tumor growth in rats J. Natl. Cancer Inst. 62 2 Feb. 1979 387 395 (Pubitemid 9094732)
56. T. Nederman, J. Carlsson, and M. Malmqvist Penetration of substances into tumor tissue - a methodological study on cellular spheroids In Vitro 17 4 Apr. 1981 290 298 (Pubitemid 12251547)
57. R. Timpl, G.R. Martin, P. Bruckner, G. Wick, and H. Wiedemann Nature of the collagenous protein in a tumor basement membrane Eur. J. Biochem. 84 1 Mar. 1978 43 52 (Pubitemid 8286686)
58. J.R. Levick Flow through interstitium and other fibrous matrices Q. J. Exp. Physiol. 72 4 Jan. 1987 409 437
59. E.J. Potchen, A.J. Elliott, B.A. Siegel, R. Studer, and R.G. Evens Pathophysiologic basis of soft tissue tumor scanning J. Surg. Oncol. 3 6 1971 593 602
60. V.J. Richardson, B.E. Ryman, R.F. Jewkes, K. Jeyasingh, M.N. Tattersall, E.S. Newlands, and S.B. Kaye Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patients Br. J. Cancer 40 1 Jul. 1979 35 43 (Pubitemid 9225975)
61. G. Gregoriadis, D.E. Neerunjun, and R. Hunt Fate of a liposome-associated agent injected into normal and tumour-bearing rodents. Attempts to improve localization in tumour tissues Life Sci. 21 3 1977 357 369 (Pubitemid 8191972)
62. L. Grislain, P. Couvreur, V. Lenaerts, M. Roland, D. Deprez-Decampeneere, and P. Speiser Pharmacokinetics and distribution of a biodegradable drug-carrier Int. J. Pharm. 15 3 1983 335 345 (Pubitemid 13071661)
63. R.T. Proffitt, L.E. Williams, C.A. Presant, G.W. Tin, J.A. Uliana, R.C. Gamble, and J.D. Baldeschwieler Tumor-imaging potential of liposomes loaded with In-111-NTA: biodistribution in mice J. Nucl. Med. 24 1 Jan. 1983 45 51 (Pubitemid 13189999)
64. V.J. Richardson, K. Jeyasingh, R.F. Jewkes, B.E. Ryman, and M.H. Tattersall Properties of [99mTc] technetium-labelled liposomes in normal and tumour-bearing rats Biochem. Soc. Trans. 5 1 Jan. 1977 290 291 (Pubitemid 8063587)
65. K.J. Widder, A.E. Senyei, and B. Sears Experimental methods in cancer therapeutics J. Pharm. Sci. 71 4 Apr. 1982 379 387 (Pubitemid 12123794)
66. V.J. Richardson, K. Jeyasingh, R.F. Jewkes, B.E. Ryman, and M.H. Tattersall Possible tumor localization of Tc-99m-labeled liposomes: effects of lipid composition, charge, and liposome size J. Nucl. Med. 19 9 Sep. 1978 1049 1054 (Pubitemid 8392298)
67. T.P. Butler, F.H. Grantham, and P.M. Gullino Bulk transfer of fluid in the interstitial compartment of mammary tumors Cancer Res. 35 11 Pt 1 Nov. 1975 3084 3088
68. A.A. Gabizon, and D. Papahadjopoulos Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors Proc. Natl. Acad. Sci. 85 18 Sep. 1988 6949 6953
69. T. Allen, and J. Everest Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats J. Pharmacol. Exp. Ther. 226 2 Aug. 1983 539 544 (Pubitemid 13041534)
70. I.H. Goldberg Free radical mechanisms in neocarzinostatin-induced DNA damage Free Radic. Biol. Med. 3 1 1987 41 54 (Pubitemid 18075119)
71. S.-K. Sim, and J. William Lown The mechanism of the neocarzinostatin- induced cleavage of DNA Biochem. Biophys. Res. Commun. 81 1 1978 99 105
72. H. Maeda SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy Adv. Drug Deliv. Rev. 46 1-3 Mar. 1991 169 185
73. H. Maeda, Y. Sano, J. Takeshita, Z. Iwai, H. Kosaka, T. Marubayashi, and Y. Matsukado A pharmacokinetic simulation model for chemotherapy of brain tumor with an antitumor protein antibiotic, neocarzinostatin Cancer Chemother. Pharmacol. 5 4 Jun. 1981 243 249
74. T. Oda, F. Sato, H. Yamamoto, M. Akagi, and H. Maeda Cytotoxicity of SMANCS in comparison with other anticancer agents against various cells in culture Anticancer Res. 9 2 1989 261 266 (Pubitemid 19174623)
75. S. Hirayama, F. Sato, T. Oda, and H. Maeda Stability of high molecular weight anticancer agent SMANCS and its transfer from oil-phase to water-phase. Comparative study with neocarzinostatin Jpn. J. Antibiot. 39 3 Mar. 1986 815 822 (Pubitemid 16067347)
76. H. Maeda, M. Ueda, T. Morinaga, and T. Matsumoto Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties J. Med. Chem. 28 4 Apr. 1985 455 461 (Pubitemid 15108801)
77. T. Konno, H. Maeda, I. Yokoyama, K. Iwai, K. Ogata, S. Tashiro, K. Uemura, M. Mochinaga, E. Watanabe, K. Nakakuma, T. Morinaga, and Y. Miyauchi Use of a lipid lymphographic agent, lipiodol, as a carrier of high molecular weight antitumor agent, SMANCS, for hepatocellular carcinoma Gan To Kagaku Ryoho 9 11 Nov. 1982 2005 2015 (Pubitemid 13179828)
78. N. Ohtsuka, T. Konno, Y. Miyauchi, and H. Maeda Anticancer effects of arterial administration of the anticancer agent SMANCS with lipiodol on metastatic lymph nodes Cancer 59 9 May 1987 1560 1565 (Pubitemid 17060095)
79. H. Maeda, T. Sawa, and T. Konno Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS J. Control. Release 74 1-3 Jul. 2001 47 61 (Pubitemid 32727608)
80. T. Kanematsu, K. Inokuchi, K. Sugimachi, T. Furuta, T. Sonoda, S. Tamura, and K. Hasuo Selective effects of lipiodolized antitumor agents J. Surg. Oncol. 25 3 Mar. 1984 218 226 (Pubitemid 14132618)
81. J.L. Raoul, R. Duvauferrier, P. Bourguet, J.F. Bretagne, S. Coornaert, P. Darnault, Y. Deugnier, J.Y. Herry, and J. Gastard Lipiodolized angiography in hepatocellular carcinomas. Contribution of iodine-131-labelled lipiodol J. Radiol. 67 11 Nov. 1986 797 801
82. T. Imaeda, Y. Yamawaki, M. Seki, H. Goto, G. Iinuma, M. Kanematsu, R. Mochizuki, H. Doi, S. Saji, and K. Shimokawa Lipiodol retention and massive necrosis after lipiodol-chemoembolization of hepatocellular carcinoma: correlation between computed tomography and histopathology Cardiovasc. Intervent. Radiol. 16 4 1993 209 213 (Pubitemid 23204501)
83. Z. Kan, K. Ivancev, I. Hägerstrand, V.P. Chuang, and A. Lunderquist In Vivo Microscopy of the Liver after Injection of Lipiodol into the Hepatic Artery and Portal Vein in the Rat Acta Radiol. 30 4 Jan. 2010 419 425
84. T. Irie, M. Kuramochi, and N. Takahashi Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure Cardiovasc. Intervent. Radiol. 36 3 Jun. 2013 706 713
85. G. Pelletier, M. Ducreux, F. Gay, M. Luboinski, H. Hagège, T. Dao, W. Van Steenbergen, C. Buffet, P. Rougier, M. Adler, J.P. Pignon, and A. Roche Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC J. Hepatol. 29 1 Jul. 1998 129 134 (Pubitemid 28307992)
86. O. Matsui, T. Takashima, M. Kadoya, K. Kitagawa, J. Hirose, T. Kameyama, S. Choutou, and S. Miyata Mechanism of lipiodol accumulation and retention in hepatic tumors - analysis in cases of simple lipiodol injection Nihon Igaku Hoshasen Gakkai Zasshi 47 11 Nov. 1987 1395 1404
87. T. Konno Targeting chemotherapy for hepatoma: arterial administration of anticancer drugs dissolved in lipiodol Eur. J. Cancer 28 2 1992 403 409
88. K. Iwai, H. Maeda, and T. Konno Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image Cancer Res. 44 5 May 1984 2115 2121 (Pubitemid 14145739)
89. H. Maeda, T. Matsumoto, T. Konno, K. Iwai, and M. Ueda Tailor-making of protein drugs by polymer conjugation for tumor targeting: a brief review on SMANCS J. Protein Chem. 3 2 Apr. 1984 181 193 (Pubitemid 14046603)
90. T. Konno, H. Maeda, K. Iwai, S. Tashiro, S. Maki, S. Morinaga, T. Morinaga, M. Mochinaga, T. Hiraoka, and I. Yokoyama Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report Eur. J. Cancer Clin. Oncol. 19 8 1983 1053 1061
91. S.C. Owen, A.K. Doak, P. Wassam, M.S. Shoichet, and B.K. Shoichet Colloidal aggregation affects the efficacy of anticancer drugs in cell culture ACS Chem. Biol. 7 8 Aug. 2012 1429 1435
92. Y. Matsumura, T. Oda, and H. Maeda General mechanism of intratumor accumulation of macromolecules: advantage of macromolecular therapeutics Gan To Kagaku Ryoho 14 3 Pt 2 Mar. 1987 821 829 (Pubitemid 17041105)
93. H. Maeda, L.W. Seymour, and Y. Miyamoto Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo Bioconjug. Chem. 3 5 Sep. 1992 351 362
94. R. Duncan, L.W. Seymour, K.B. O'Hare, P.A. Flanagan, S. Wedge, I.C. Hume, K. Ulbrich, J. Strohalm, V. Subr, F. Spreafico, M. Grandi, M. Ripamonti, M. Farao, and A. Suarato Preclinical evaluation of polymer-bound doxorubicin J. Control. Release 19 1-3 Mar. 1992 331 346
95. L.W. Seymour Passive tumor targeting of soluble macromolecules and drug conjugates Crit. Rev. Ther. Drug Carrier Syst. 9 2 Jan. 1992 135 187
96. J.M. Harris, and R.B. Chess Effect of pegylation on pharmaceuticals Nat. Rev. Drug Discov. 2 3 Mar. 2003 214 221 (Pubitemid 37361666)
97. A. Abuchowski, J.R. McCoy, N.C. Palczuk, T. van Es, and F.F. Davis Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase J. Biol. Chem. 252 11 Jun. 1977 3582 3586 (Pubitemid 8116088)
98. T. Lammers, G. Pasut, and F.M. Veronese State of the art in PEGylation: the great versatility achieved after forty years of research J. Control. Release 161 2 2012 461 472
99. J.-W. Yoo, E. Chambers, and S. Mitragotri Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects Curr. Pharm. Des. 16 21 Jul. 2010 2298 2307
100. M. Schuler, D. Trentin, M. Textor, and S.G.P. Tosatti Biomedical interfaces: titanium surface technology for implants and cell carriers Nanomedicine (Lond) 1 4 Dec. 2006 449 463
101. M.S. Hershfield, R.H. Buckley, M.L. Greenberg, A.L. Melton, R. Schiff, C. Hatem, J. Kurtzberg, M.L. Markert, R.H. Kobayashi, and A.L. Kobayashi Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase N. Engl. J. Med. 316 10 Mar. 1987 589 596 (Pubitemid 17024481)
102. N.V. Katre The conjugation of proteins with polyethylene glycol and other polymers Adv. Drug Deliv. Rev. 10 1 Jan. 1993 91 114
103. K. Kitajima, and M. Fukuoka Studies on the appropriate administration of cisplatin based on pharmacokinetics and toxicity Gan to kagaku ryoho 14 8 Aug. 1987 2517 2523 (Pubitemid 18051281)
104. R.L. Juliano, and D. Stamp Pharmacokinetics of liposome-encapsulated anti-tumor drugs Biochem. Pharmacol. 27 1 1978 21 27
105. M. Ostro, and P. Cullis Use of liposomes as injectable-drug delivery systems Am. J. Health Syst. Pharm. 46 8 Aug. 1989 1576 1587 (Pubitemid 19201630)
106. A. Soundararajan, A. Bao, W.T. Phillips, R. Perez, and B.A. Goins [(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model Nucl. Med. Biol. 36 5 Jul. 2009 515 524
107. M. Winterhalter, and D.D. Lasic Liposome stability and formation: experimental parameters and theories on the size distribution Chem. Phys. Lipids 64 1 1993 35 43 (Pubitemid 23290864)
108. A.A. Gabizon Liposome circulation time and tumor targeting: implications for cancer chemotherapy Adv. Drug Deliv. Rev. 16 2-3 Sep. 1995 285 294
109. T.M. Allen, C. Hansen, F. Martin, C. Redemann, and A. Yau-Young Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo Biochim. Biophys. Acta Biomembr. 1066 1 1991 29 36
110. A.J. Bradley, D.V. Devine, S.M. Ansell, J. Janzen, and D.E. Brooks Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids Arch. Biochem. Biophys. 357 2 Sep. 1998 185 194 (Pubitemid 28419200)
111. J. Szebeni, P. Bedocs, and Z. Rozsnyay Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome Nanomedicine 8 2 Feb. 2012 176 184
112. D.D. Von Hoff, M.W. Layard, P. Basa, H.L. Davis, A.L. Von Hoff, M. Rozencweig, and F.M. Muggia Risk factors for doxorubicin-induced congestive heart failure Ann. Intern. Med. 91 5 Nov. 1979 710 717 (Pubitemid 10218041)
113. D.L. Keefe Anthracycline-induced cardiomyopathy Semin. Oncol. 28 No.4 Suppl. 12 Aug. 2001 2 7 (Pubitemid 32879934)
114. L.D. Mayer, M.B. Bally, M.J. Hope, and P.R. Cullis Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential Biochim. Biophys. Acta 816 2 Jun. 1985 294 302 (Pubitemid 15047328)
115. Y. Barenholz Doxil(r) - the first FDA-approved nano-drug: lessons learned J. Control. Release 160 2 Jun. 2012 117 134
116. D. Papahadjopoulos, T.M. Allen, A.A. Gabizon, E. Mayhew, K. Matthay, S.K. Huang, K.D. Lee, M.C. Woodle, D.D. Lasic, and C. Redemann Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy Proc. Natl. Acad. Sci. 88 24 Dec. 1991 11460 11464 (Pubitemid 21916061)
117. P. Working, and M. Newman Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth(r) liposomes (Doxil(r)) Liposome 4 1 Jan. 1994 667 687 (Pubitemid 24130564)
118. D.E. Owens, and N.A. Peppas Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles Int. J. Pharm. 307 no. 1 Jan. 2006 93 102 (Pubitemid 41773257)
119. A.A. Gabizon, Y. Barenholz, and M. Bialer Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs Pharm. Res. 10 5 May 1993 703 708 (Pubitemid 23152316)
120. A.A. Gabizon, R. Catane, B. Uziely, B. Kaufman, T. Safra, R. Cohen, F. Martin, A. Huang, and Y. Barenholz Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes Cancer Res. 54 4 Feb. 1994 987 992 (Pubitemid 24085451)
121. M.S. Ewer, F.J. Martin, C. Henderson, C.L. Shapiro, R.S. Benjamin, and A.A. Gabizon Cardiac safety of liposomal anthracyclines Semin. Oncol. 31 no.6 Suppl. 13 Dec. 2004 161 181 (Pubitemid 40023246)
122. P.K. Working, and A.D. Dayan Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl) Hum. Exp. Toxicol. 15 9 1996 751 785 (Pubitemid 26331691)
123. D.W. Northfelt, F.J. Martin, P. Working, P.A. Volberding, J. Russell, M. Newman, M.A. Amantea, and L.D. Kaplan Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS related kaposi's sarcoma J. Clin. Pharmacol. 36 1 Jan. 1996 55 63 (Pubitemid 26058811)
124. Z. Symon, A. Peyser, D. Tzemach, O. Lyass, E. Sucher, E. Shezen, and A.A. Gabizon Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes Cancer 86 1 Jul. 1999 72 78 (Pubitemid 29293379)
125. 2 Ann. Oncol. 11 8 Aug. 2000 1029 1033
126. FDA Drug Label - Doxil 1995 1 35
127. D. Northfelt, B. Dezube, J. Thommes, B. Miller, M. Fischl, A. Friedman-Kien, L. Kaplan, C.Du. Mond, R. Mamelok, and D. Henry Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial J. Clin. Oncol. 16 7 Jul. 1998 2445 2451 (Pubitemid 28309039)
128. S. Stewart, H. Jablonowski, F. Goebel, K. Arasteh, M. Spittle, A. Rios, D. Aboulafia, J. Galleshaw, and B. Dezube Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group J. Clin. Oncol. 16 2 Feb. 1998 683 691 (Pubitemid 28135616)
129. R.Z. Orlowski, A. Nagler, P. Sonneveld, J. Bladé, R. Hajek, A. Spencer, J. San Miguel, T. Robak, A. Dmoszynska, N. Horvath, I. Spicka, H.J. Sutherland, A.N. Suvorov, S.H. Zhuang, T. Parekh, L. Xiu, Z. Yuan, W. Rackoff, and J.-L. Harousseau Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression J. Clin. Oncol. 25 25 Sep. 2007 3892 3901 (Pubitemid 47477266)
130. M.E.R. O'Brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D.G. Kieback, P. Tomczak, S.P. Ackland, F. Orlandi, L. Mellars, L. Alland, and C. Tendler Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYXTM/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann. Oncol. 15 3 Mar. 2004 440 449 (Pubitemid 38444547)
131. A.A. Gabizon, H. Shmeeda, and Y. Barenholz Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies Clin. Pharmacokinet. 42 5 Jan. 2003 419 436 (Pubitemid 36649037)
132. D.N. Waterhouse, P.G. Tardi, L.D. Mayer, and M.B. Bally A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles Drug Saf. 24 12 Jan. 2001 903 920 (Pubitemid 33078196)
133. A.L. van de Ven, P. Kim, O. Haley, J.R. Fakhoury, G. Adriani, J. Schmulen, P. Moloney, F. Hussain, M. Ferrari, X. Liu, S.-H. Yun, and P. Decuzzi Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution J. Control. Release 158 1 Feb. 2012 148 155
134. S.K. Hobbs, W.L. Monsky, F. Yuan, W.G. Roberts, L. Griffith, V.P. Torchilin, and R.K. Jain Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment Proc. Natl. Acad. Sci. 95 8 Apr. 1998 4607 4612 (Pubitemid 28207960)
135. H. Maeda, J. Fang, T. Inutsuka, and Y. Kitamoto Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications Int. Immunopharmacol. 3 3 Mar. 2003 319 328 (Pubitemid 36293960)
136. T. Minko, P. Kopeckova, V. Pozharov, K.D. Jensen, and J. Kopecek The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumors Pharm. Res. 17 5 May 2000 505 514 (Pubitemid 30416386)
137. H.F. Dvorak Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels J. Exp. Med. 174 5 Nov. 1991 1275 1278
138. H.F. Dvorak, J.A. Nagy, and A.M. Dvorak Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies Cancer Cells 3 3 Mar. 1991 77 85
139. H. Hashizume, P. Baluk, S. Morikawa, J.W. McLean, G. Thurston, S. Roberge, R.K. Jain, and D.M. McDonald Openings between defective endothelial cells explain tumor vessel leakiness Am. J. Pathol. 156 4 Apr. 2000 1363 1380 (Pubitemid 30660013)
140. Y. Ichinose, T. Yano, H. Yokoyama, T. Inoue, H. Asoh, and Y. Katsuda The correlation between tumor size and lymphatic vessel invasion in resected peripheral stage I non-small-cell lung cancer. A potential risk of limited resection J. Thorac. Cardiovasc. Surg. 108 4 Oct. 1994 684 686 (Pubitemid 24330245)
141. G. Kwon, S. Suwa, M. Yokoyama, T. Okano, Y. Sakurai, and K. Kataoka Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly(ethylene oxide-aspartate) block copolymer-adriamycin conjugates J. Control. Release 29 1-2 1994 17 23
142. A. Bao, B. Goins, R. Klipper, G. Negrete, and W.T. Phillips Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies J. Pharmacol. Exp. Ther. 308 2 Feb. 2004 419 425 (Pubitemid 38134199)
143. S.W.C.W.C. Kim, D.W. Kim, Y.H. Shim, J.S. Bang, H.S. Oh, S. Wan Kim, and M.H. Seo In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy J. Control. Release 72 1-3 May 2001 191 202 (Pubitemid 32522357)
144. Z.G. Gao, D.H. Lee, D.I. Kim, and Y.H. Bae Doxorubicin loaded pH-sensitive micelle targeting acidic extracellular pH of human ovarian A2780 tumor in mice J. Drug Target. 13 7 Aug. 2005 391 397 (Pubitemid 43084539)
145. O. Ishida, K. Maruyama, K. Sasaki, and M. Iwatsuru Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice Int. J. Pharm. 190 1 1999 49 56 (Pubitemid 29467471)
146. K.J. Harrington, S. Mohammadtaghi, P.S. Uster, D. Glass, A.M. Peters, R.G. Vile, and J.S.W. Stewart Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes Clin. Cancer Res. 7 2001 243 254 (Pubitemid 32183025)
147. R.K. Jain Vascular and interstitial barriers to delivery of therapeutic agents in tumors Cancer Metastasis Rev. 9 3 Nov. 1990 253 266 (Pubitemid 20380382)
148. Y.S. Chang, E. di Tomaso, D.M. McDonald, R. Jones, R.K. Jain, and L.L. Munn Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood Proc. Natl. Acad. Sci. U. S. A. 97 26 Dec. 2000 14608 14613 (Pubitemid 32016623)
149. J.R. Less, T.C. Skalak, E.M. Sevick, and R.K. Jain Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions Cancer Res. 51 1991 265 273
150. J.W. Baish, T. Stylianopoulos, R.M. Lanning, W.S. Kamoun, D. Fukumura, L.L. Munn, and R.K. Jain Scaling rules for diffusive drug delivery in tumor and normal tissues Proc. Natl. Acad. Sci. U. S. A. 108 5 Feb. 2011 1799 1803
151. D. Fukumura, D.G. Duda, L.L. Munn, and R.K. Jain Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models Microcirculation 17 3 Apr. 2010 206 225
152. R.J. Gillies, P.A. Schornack, T.W. Secomb, and N. Raghunand Causes and effects of heterogeneous perfusion in tumors Neoplasia 1 3 Aug. 1999 197 207
153. X. Hu, R.H. Adamson, B. Liu, F.E. Curry, and S. Weinbaum Starling forces that oppose filtration after tissue oncotic pressure is increased Am. J. Physiol. Heart Circ. Physiol. 279 4 Oct. 2000 H1724 H1736
154. Y. Boucher, and R.K. Jain Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse Cancer Res. 52 1992 5110 5114
155. P.A. Netti, L.T. Baxter, Y. Boucher, R. Skalak, and R.K. Jain Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery Cancer Res. 55 22 Nov. 1995 5451 5458
156. Y. Boucher, M. Leunig, and R.K. Jain Tumor angiogenesis and interstitial
157. R. Gutmann, M. Leunig, J. Feyh, A.E. Goetz, K. Messmer, E. Kastenbauer, and R.K. Jain Interstitial hypertension in head and neck tumors in patients: correlation with tumor size Cancer Res. 52 7 Apr. 1992 1993 1995
158. Y. Boucher, L.T. Baxter, and R.K. Jain Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy Cancer Res. 50 15 Aug. 1990 4478 4484 (Pubitemid 20230379)
159. Y. Boucher, H. Salehi, B. Witwer, G.R. Harsh, and R.K. Jain Interstitial fluid pressure in intracranial tumours in patients and in rodents Br. J. Cancer 75 6 Jan. 1997 829 836 (Pubitemid 27110698)
160. Y. Navalitloha, E.S. Schwartz, E.N. Groothuis, C.V. Allen, R.M. Levy, and D.R. Groothuis Therapeutic implications of tumor interstitial fluid pressure in subcutaneous RG-2 tumors Neurol. Oncol. 8 3 Jul. 2006 227 233 (Pubitemid 46542647)
161. T. Licht, H.H. Fiebig, K.J. Bross, F. Herrmann, D.P. Berger, R. Shoemaker, and R. Mertelsmann Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro Int. J. Cancer J. Int. Cancer 49 4 1991 630 637
162. M.F. Flessner, J. Choi, K. Credit, R. Deverkadra, and K. Henderson Resistance of tumor interstitial pressure to the penetration of intraperitoneally delivered antibodies into metastatic ovarian tumors Clin. Cancer Res. 11 8 Apr. 2005 3117 3125 (Pubitemid 40525219)
163. S.B. Fox, K.C. Gatter, R. Bicknell, J.J. Going, P. Stanton, T.G. Cooke, and A.L. Harris Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer Cancer Res. 53 18 Sep. 1993 4161 4163 (Pubitemid 24146759)
164. J. Holash, S.J. Wiegand, and G.D. Yancopoulos New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF Oncogene 18 38 Sep. 1999 5356 5362 (Pubitemid 29462372)
165. B.A. Graff, I.C. Benjaminsen, K.G. Brurberg, E.-B.M. Ruud, and E.K. Rofstad Comparison of tumor blood perfusion assessed by dynamic contrast-enhanced MRI with tumor blood supply assessed by invasive imaging J. Magn. Reson. Imaging 21 no. 3 Mar. 2005 272 281 (Pubitemid 40280122)
166. F. Yuan, M. Leunig, and S. Huang Mirovascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft Cancer Res. 54 13 1994 3352 3356 (Pubitemid 24225946)
167. S. Ramanujan, A. Pluen, T.D. McKee, E.B. Brown, Y. Boucher, and R.K. Jain Diffusion and convection in collagen gels: implications for transport in the tumor interstitium Biophys. J. 83 3 Sep. 2002 1650 1660 (Pubitemid 34977735)
168. A. Pluen, Y. Boucher, S. Ramanujan, T.D. McKee, T. Gohongi, E. di Tomaso, E.B. Brown, Y. Izumi, R.B. Campbell, D.A. Berk, and R.K. Jain Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors Proc. Natl. Acad. Sci. U. S. A. 98 no. 8 Apr. 2001 4628 4633 (Pubitemid 32295027)
169. T. Stylianopoulos, M.-Z. Poh, N. Insin, M.G. Bawendi, D. Fukumura, L.L. Munn, and R.K. Jain Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions Biophys. J. 99 5 Sep. 2010 1342 1349
170. L. Eikenes, ∅.S. Bruland, C. Brekken, and C.D.L. Davies Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts Cancer Res. 64 14 Jul. 2004 4768 4773 (Pubitemid 38930817)
171. T.T. Goodman, P.L. Olive, and S.H. Pun Increased nanoparticle penetration in collagenase-treated multicellular spheroids Int. J. Nanomedicine 2 2 Jan. 2007 265 274 (Pubitemid 47224508)
172. L. Eikenes, M. Tari, I. Tufto, O.S. Bruland, and C. de Lange Davies Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts Br. J. Cancer 93 1 Jul. 2005 81 88 (Pubitemid 41078799)
173. G. Kong, R.D. Braun, and M.W. Dewhirst Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size Cancer Res. 60 16 Aug. 2000 4440 4445 (Pubitemid 32103623)
174. D. Thakkar, R. Gupta, K. Monson, and N. Rapoport Effect of ultrasound on the permeability of vascular wall to nano-emulsion droplets Ultrasound Med. Biol. 39 10 2013 1804 1811
175. R.K. Jain Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 5706 Jan. 2005 58 62 (Pubitemid 40093472)
176. V.P. Chauhan, T. Stylianopoulos, J.D. Martin, Z. Popović, O. Chen, W.S. Kamoun, M.G. Bawendi, D. Fukumura, and R.K. Jain Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner Nat. Nanotechnol. 7 6 Jun. 2012 383 388
177. R.K. Jain Molecular regulation of vessel maturation Nat. Med. 9 6 Jun. 2003 685 693 (Pubitemid 36749217)
178. P. Gill, J. Wernz, D. Scadden, P. Cohen, G. Mukwaya, J. von Roenn, M. Jacobs, S. Kempin, I. Silverberg, G. Gonzales, M. Rarick, A. Myers, F. Shepherd, C. Sawka, M. Pike, and M. Ross Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma J. Clin. Oncol. 14 8 Aug. 1996 2353 2364 (Pubitemid 26264888)
179. S. Chan, N. Davidson, E. Juozaityte, F. Erdkamp, A. Pluzanska, N. Azarnia, and L.W. Lee Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer Ann. Oncol. 15 10 Oct. 2004 1527 1534 (Pubitemid 39409744)
180. W.J.W. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar, M. Hawkins, and J. O'Shaughnessy Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J. Clin. Oncol. 23 31 Nov. 2005 7794 7803 (Pubitemid 46657376)
181. A. Gordon, and J. Fleagle Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J. Clin. 19 14 Jul. 2001 3312 3322 (Pubitemid 32642183)
182. D.G. Mutch, M. Orlando, T. Goss, M.G. Teneriello, A.N. Gordon, S.D. McMeekin, Y. Wang, D.R. Scribner, M. Marciniack, R.W. Naumann, and A.A. Secord Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer J. Clin. Oncol. 25 19 Jul. 2007 2811 2818 (Pubitemid 47123191)
183. R. Rifkin, S. Gregory, A. Mohrbacher, and M. Hussein dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple Cancer 106 4 Feb. 2006 848 858
184. L. Guillou, and C. Fletcher Benign lymphangioendothelioma (acquired progressive lymphangioma): a lesion not to be confused with well-differentiated angiosarcoma and patch stage Kaposi's sarcoma: clinicopathologic analysis of a series Am. J. Surg. 2000
185. M.J. Levi Classic Kaposi's sarcoma J. Am. Podiatr. Med. Assoc. 95 6 Nov. 2005 586 588 (Pubitemid 41771798)
186. Y.-K. Hong, K. Foreman, J.W. Shin, S. Hirakawa, C.L. Curry, D.R. Sage, T. Libermann, B.J. Dezube, J.D. Fingeroth, and M. Detmar Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus Nat. Genet. 36 7 Jul. 2004 683 685 (Pubitemid 38886627)
187. A. Silva, A.R.A. Anderson, and R. Gatenby A multiscale model of the bone marrow and hematopoiesis Math. Biosci. Eng. 8 2 Apr. 2011 643 658
188. A. Vacca, D. Ribatti, L. Roncali, G. Ranieri, G. Serio, F. Silvestris, and F. Dammacco Bone marrow angiogenesis and progression in multiple myeloma Br. J. Haematol. 87 3 Jul. 1994 503 508 (Pubitemid 24230014)
189. D.S. Alberts, F.M. Muggia, J. Carmichael, E.P. Winer, M. Jahanzeb, A.P. Venook, K.M. Skubitz, E. Rivera, J.A. Sparano, N.J. DiBella, S.J. Stewart, J.J. Kavanagh, and A.A. Gabizon Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials Semin. Oncol. 31 6 Suppl. 13 Dec. 2004 53 90 (Pubitemid 40023242)
190. J. Eckes, O. Schmah, J.W. Siebers, U. Groh, S. Zschiedrich, B. Rautenberg, A. Hasenburg, M. Jansen, M.J. Hug, K. Winkler, and G. Pütz Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial) BMC Cancer 11 no. 1 Jan. 2011 337
191. M. Amantea, M.S. Newman, T.M. Sullivan, A. Forrest, and P.K. Working Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs Hum. Exp. Toxicol. 18 1 Jan. 1999 17 26 (Pubitemid 29054468)
192. FDA Fast Track Designation for Myocet for Metastatic Breast Cancer Oncol. Times 32 no. 3 2010 24
193. M.R. Green, G.M. Manikhas, S. Orlov, B. Afanasyev, A.M. Makhson, P. Bhar, and M.J. Hawkins Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer Ann. Oncol. 17 8 Aug. 2006 1263 1268 (Pubitemid 44288216)
194. A. Sparreboom, L. van Zuylen, E. Brouwer, W.J. Loos, P. de Bruijn, H. Gelderblom, M. Pillay, K. Nooter, G. Stoter, and J. Verweij Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications Cancer Res. 59 7 Apr. 1999 1454 1457 (Pubitemid 29160110)
195. P.H. Wiernik, E.L. Schwartz, J.J. Strauman, J.P. Dutcher, R.B. Lipton, and E. Paietta Phase I clinical and pharmacokinetic study of taxol Cancer Res. 47 9 May 1987 2486 2493 (Pubitemid 17099218)
196. E. Miele, G.P. Spinelli, E. Miele, F. Tomao, and S. Tomao Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer Int. J. Nanomedicine 4 Jan. 2009 99 105
197. A.J. ten Tije, J. Verweij, W.J. Loos, and A. Sparreboom Pharmacological effects of formulation vehicles Clin. Pharmacokinet. 42 7 2003 665 685
198. R. Kim, M. Emi, and K. Tanabe Cancer immunoediting from immune surveillance to immune escape Immunology 121 1 May 2007 1 14 (Pubitemid 46537674)
199. M. Egeblad, E.S. Nakasone, and Z. Werb Tumors as organs: complex tissues that interface with the entire organism Dev. Cell 18 6 Jun. 2010 884 901
200. Y.P. Choi, H.S. Shim, M.-Q. Gao, S. Kang, and N.H. Cho Molecular portraits of intratumoral heterogeneity in human ovarian cancer Cancer Lett. 307 1 Aug. 2011 62 71
201. K.S. Lee, H.C. Chung, S.A. Im, Y.H. Park, C.S. Kim, S.-B. Kim, S.Y. Rha, M.Y. Lee, and J. Ro Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer Breast Cancer Res. Treat. 108 2 Mar. 2008 241 250 (Pubitemid 351311357)
202. F.J. Esteva Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer J. Clin. Oncol. 20 7 Apr. 2002 1800 1808 (Pubitemid 34273269)
203. M.M. Gottesman How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation award lecture Cancer Res. 53 1993 747 754 (Pubitemid 23077856)
204. J. Baker, J. Ajani, F. Scotté, D. Winther, M. Martin, M.S. Aapro, and G. von Minckwitz Docetaxel-related side effects and their management Eur. J. Oncol. Nurs. 13 1 Feb. 2009 49 59
205. V. Wagner, A. Dullaart, A.-K. Bock, and A. Zweck The emerging nanomedicine landscape Nat. Biotechnol. 24 10 Oct. 2006 1211 1217 (Pubitemid 44564760)
206. J. Ross, and J. Fletcher The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy Oncologist 3 4 Jan. 1998 237 252
207. E.S. Lee, Z. Gao, D. Kim, K. Park, I.C. Kwon, Y.H. Bae, E. Seong, I. Chan, and Y. Han Super pH-sensitive multifunctional polymeric micelle for tumor pHe specific TAT exposure and multidrug resistance J. Control. Release 129 3 2008 228 236
208. S.B. Horwitz Taxol (paclitaxel): mechanisms of action Ann. Oncol. 5 Suppl. 6 Jan. 1994 S3 S6
209. H. Mizutani, S. Tada-Oikawa, Y. Hiraku, M. Kojima, and S. Kawanishi Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide Life Sci. 76 13 2005 1439 1453 (Pubitemid 40164773)
210. G. Melillo Targeting hypoxia cell signaling for cancer therapy Cancer Metastasis Rev. 26 2 Jun. 2007 341 352 (Pubitemid 47101663)
211. N.A. Peppas, and R.K. Jain Delivery of molecular and cellular medicine to solid tumors Adv. Drug Deliv. Rev. 64 2012 353 365